MaxCyte (MXCT) has released an update.
MaxCyte, Inc., a prominent cell-engineering company, announced that Non-Executive Director Stanley Erck exercised options and sold 47,689 shares of the company’s common stock. The shares were sold at prices ranging from $3.610 to $3.755, representing 8.04% of his total equity and option holdings. Following the transaction, Erck retains 247,751 shares, highlighting active insider trading activity within MaxCyte.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
